Treatment-free remission (TFR) - CML - Chronic Myeloid Leukemia
Treatment-free remission in CML refers of maintenance of deep molecular response without continuing TKI therapy after achieving undetectable molecular residual disease (UMRD)
Important notice: You must inform your CML doctor or a qualified doctor if you want to stop your medication. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.... See our disclamer
"Treatment-free remission (TFR) has recently emerged as a goal of treatment in chronic myeloid leukaemia (CML). Molecular remission is sustained in around 30% of imatinib-treated patients who stop treatment after ≥2 years with undetectable minimal residual disease (UMRD) by conventional real-time reverse transcription polymerase chain reaction. An additional 20–30% of patients will lose UMRD, but remain in stable major molecular remission off treatment. Most patients with molecular recurrence have a significant increase in BCR-ABL1 within the first 6 months off treatment, but there are also rare late relapses. As re-treatment with imatinib restores control, a trial of TFR is safe so long as careful molecular monitoring is provided to enable prompt re-treatment. The minimum eligibility criteria for a trial of TFR are not yet defined, but the available data support a MRD level of around a molecular response of 4·5 log for at least 2 years. Factors associated with a higher probability of TFR include low risk Sokal score, prior interferon treatment, longer total duration of imatinib treatment and higher numbers of natural killer cells at the time of imatinib discontinuation. Preliminary data suggest that the rate of TFR in patients treated with more potent tyrosine kinase inhibitors will probably be higher. The biology that underlies TFR is an area of active investigation."
Extract of " How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia ".
VIDEOS
Adelaide researchers discover new blood test to help stop leukaemia | 7NEWS
October 2023, 7NEWS Australia
Factors associated with successful TFR in patients with CML who have discontinued TKI therapy
2022, VJHemOnc – Video Journal of Hematology & HemOnc
Is it possible to achieve TFR with low-dose TKI therapy?
October 25, 2022, VJHemOnc – Video Journal of Hematological Oncology
VIDEO: Understanding treatment-free remission in chronic myeloid leukemia
April 19, 2022, Healio
CML Treatment Free Remission/Stopping Tasigna (Nilotinib)/Chronic Myeloid Leukemia Cessation/CML TFR
April 30, 2021, HEAL Every Day Together
CML Horizons 2020 Medical #3: Treatment-free remission
November 2020, CML Advocates Network
Getting CML Patients Into a Deeper Treatment Response - Dr. Jerry Radich
December 20, 2019, Patient Power
Massimo Breccia, ASH 2019: Chronic Myeloid Leukemia Patients after Discontinuation
December 18, 2019, Touch Medical Media
Kaliammal fron Singapore - (Remission and TFR)
September 26, 2019, Novartis Singapore
Reducing or stopping treatment - who and when?
September 21, 2019, CML Support
Treatment-Free Remission & Toxicities of Discontinuing CML Therapy
July 19, 2019, Targeted Oncology
Dr. Radich on Treatment Discontinuation in CML Off Trial
September 27, 2018, OncLive
TFR - a new treatment goal of CP-CML patients? - Dr. Delphine Rea
August 2018, iCMLf
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
May 2018, The Lancet Oncology
Treatment-free remission in chronic myeloid leukaemia
November 2, 2017, cmladvocates
World CML Day: Treatment-free remission
September 22, 2017, Leukaemia Care
Relapse After CML Treatment Discontinuation
March 23, 2017, OncLiveTV
Stopping a Cancer Drug to See If You're Cured
March 1, 2017, Associated Press
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
What is the best treatment in the next few years to achieve more treatment-free remission in CML?
July 25, 2016, VJHemOnc
Investigating cells responsible for molecular relapse in CML patients
July 29, 2016, VJHemOnc – Video Journal of Hematological Oncology
CML Stop Treatment: Dr David Ross | Rising Sun Meeting 2015
February 17, 2016, The Max Foundation
Michael Mauro Discusses Therapy-Free CML Remission
Decmber 31, 2015, OncLiveTV
The patient perspective on treatment-free remission, including support needs - Pat Elliot
May 2015, CML Horizons Barcelona
Treatment-free remission, stop trials, predictors for stopping treatment - Andreas Hochhaus
May 2015, CML Horizons Barcelona
Panel discussion: The psychology of stopping treatment
May 2015, CML Horizons Barcelona
Treatment free remission: opportunities and dangers - Alok Srivastava
March 16, 2015, iCMLf
Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia
January 10, 2014, OncLive
Can we safely stop TKI therapies? Experience from the STOP trials - Dr. Delphine Rea
December 2012, iCMLf
Adelaide researchers discover new blood test to help stop leukaemia | 7NEWS
October 2023, 7NEWS Australia
Factors associated with successful TFR in patients with CML who have discontinued TKI therapy
2022, VJHemOnc – Video Journal of Hematology & HemOnc
Is it possible to achieve TFR with low-dose TKI therapy?
October 25, 2022, VJHemOnc – Video Journal of Hematological Oncology
VIDEO: Understanding treatment-free remission in chronic myeloid leukemia
April 19, 2022, Healio
CML Treatment Free Remission/Stopping Tasigna (Nilotinib)/Chronic Myeloid Leukemia Cessation/CML TFR
April 30, 2021, HEAL Every Day Together
CML Horizons 2020 Medical #3: Treatment-free remission
November 2020, CML Advocates Network
Getting CML Patients Into a Deeper Treatment Response - Dr. Jerry Radich
December 20, 2019, Patient Power
Massimo Breccia, ASH 2019: Chronic Myeloid Leukemia Patients after Discontinuation
December 18, 2019, Touch Medical Media
Kaliammal fron Singapore - (Remission and TFR)
September 26, 2019, Novartis Singapore
Reducing or stopping treatment - who and when?
September 21, 2019, CML Support
Treatment-Free Remission & Toxicities of Discontinuing CML Therapy
July 19, 2019, Targeted Oncology
Dr. Radich on Treatment Discontinuation in CML Off Trial
September 27, 2018, OncLive
TFR - a new treatment goal of CP-CML patients? - Dr. Delphine Rea
August 2018, iCMLf
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
May 2018, The Lancet Oncology
Treatment-free remission in chronic myeloid leukaemia
November 2, 2017, cmladvocates
World CML Day: Treatment-free remission
September 22, 2017, Leukaemia Care
Relapse After CML Treatment Discontinuation
March 23, 2017, OncLiveTV
Stopping a Cancer Drug to See If You're Cured
March 1, 2017, Associated Press
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
What is the best treatment in the next few years to achieve more treatment-free remission in CML?
July 25, 2016, VJHemOnc
Investigating cells responsible for molecular relapse in CML patients
July 29, 2016, VJHemOnc – Video Journal of Hematological Oncology
CML Stop Treatment: Dr David Ross | Rising Sun Meeting 2015
February 17, 2016, The Max Foundation
Michael Mauro Discusses Therapy-Free CML Remission
Decmber 31, 2015, OncLiveTV
The patient perspective on treatment-free remission, including support needs - Pat Elliot
May 2015, CML Horizons Barcelona
Treatment-free remission, stop trials, predictors for stopping treatment - Andreas Hochhaus
May 2015, CML Horizons Barcelona
Panel discussion: The psychology of stopping treatment
May 2015, CML Horizons Barcelona
Treatment free remission: opportunities and dangers - Alok Srivastava
March 16, 2015, iCMLf
Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia
January 10, 2014, OncLive
Can we safely stop TKI therapies? Experience from the STOP trials - Dr. Delphine Rea
December 2012, iCMLf
TRIALS
European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTFreedom)
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)
Randomized Phase III Study to Assess the Effect of Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML
European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTFreedom)
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)
Randomized Phase III Study to Assess the Effect of Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML
FORUMS ON FACEBOOK
CML Patients in TFR (Treatment-Free Remission) +++ private group on Facebook
U.S. TFR/LAST Trial Participants +++ public group on Facebook
PUBLICATIONS
Chronic Myeloid Leukemia: Who Should Get a Treatment-Free Trial and How?
November 3, 2022, Canadian Hematology Today
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
December 2000, Haematologica
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
December 20, 2019, ASH Publications
Treatment-Free Remission for Chronic Myeloid Leukemia Patients
December 2018, Leukemia & Lymphoma Society
Understanding Treatment-Free Remission and How It Impacts you – Frequently Asked Questions for Patients and Advocates
September 2018, Dr. Michael J. Mauro
Chronic Myeloid Leukemia: Who Should Get a Treatment-Free Trial and How?
November 3, 2022, Canadian Hematology Today
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
December 2000, Haematologica
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
December 20, 2019, ASH Publications
Treatment-Free Remission for Chronic Myeloid Leukemia Patients
December 2018, Leukemia & Lymphoma Society
Understanding Treatment-Free Remission and How It Impacts you – Frequently Asked Questions for Patients and Advocates
September 2018, Dr. Michael J. Mauro
ARTICLES
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
December 21, 2023, Leukemia
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
November 10, 2023, Leukemia
Boosting immune system in chronic myeloid leukemia may lead to discontinuation of blood cancer drugs
November 6, 2023, Medical Xpress
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
November 2, 2023, Leukemia
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy
August 24, 2023, Blood
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
March 23, 2023, Frontiers
New therapy could help chronic myeloid leukemia patients live drug-free
March 2, 2023, The University of Adelaide
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
October 31, 2022, Dovepress
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
May 26, 2022, PubMed
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
April 7, 2022, PubMed
When is it safe to discontinue TKI therapy in people with chronic myeloid leukemia?
March 20, 2022, MedCity News
Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
November 20, 2021, PubMed
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML
November 2, 2021, PubMed
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
August 18, 2021, MDPI
Substudy to Assess CML Patients’ Perspectives on Treatment-Free Remission
June 25, 2021, Oncology Nurse Advisor
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Safe, Successful, Even Outside Clinical Trials
June 16, 2021, Oncology Nurse Advisor
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
May 26, 2021, Frontiers in Oncology
Updated Analysis of Data Demonstrates Efficacy of TFR in Chronic Myeloid Leukemia in Chronic Phase
April 9. 2021, Oncology Nurse Advisor
BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia
March 31, 2021, Oncology Nurse Advisor
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
February 15, 2021, Leukemia
Dr Atallah Assesses Outcomes Following the Discontinuation TKIs in CML
February 15,2021, Oncology Learning Network
TKI Discontinuation Found to Benefit PROs in CML, Study Says
February 6, 2021, AJMC
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML
December 15, 2020, National Cancer Institute
Clinical Challenges: Discontinuing TKIs in Chronic Myeloid Leukemia
December 11, 2020, Medpage Today
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study
December 5, 2020, ASH2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial
November 12, 2020, JamaOncology
TKI Discontinuation Safe in CML, Improved PROs
November 12, 2020, MedpageToday
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
November 10, 2020, Blood Advances
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
October 24, 2020, Taylor & Francis Online
New Path for Preventing Chronic Myelogenous Leukemia Relapse Discovered
September 21, 2020, GEN – Genetic Engineering & Biotechnology News
Evaluating treatment-free remission in patients with chronic myeloid leukemia (CML)
September 14, 2020, Medivizor
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
September 4, 2020, MDPI
Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
July 15, 2020, Clinical Lymphoma & Myeloma & Leukemia
CHARACTERIZATION OF PHENOTYPIC AND GENOTYPIC MARKERS AS PREDICTORS OF RELAPSE DURING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
SECOND GENERATION TYROSINE KINASE INHIBITORS IN THE FIRST-LINE CAN REDUCE TIME TO TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
EFFICACY AND SAFETY OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSED AFTER DISCONTINUATION OF IMATINIB FOR TREATMENT-FREE REMISSION: RESULTS OF THE FRENCH NILO POST-STIM STUDY
June 2020, EHA 2020
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY.
June 2020, EHA 2020
LATE MOLECULAR RECURRENCES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA EXPERIENCING TREATMENT FREE REMISSION.
June 2020, EHA 2020
HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY
June 2020, EHA 2020
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY
June 2020, EHA 2020
HLA POLYMORPHISMS PREDICT TREATMENT-FREE REMISSION FOLLOWING TKI DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
DOSE REDUCTION OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH MAJOR AND DEEP MOLECULAR RESPONSE
June 2020, EHA 2020
Study Provides Support for TKI Discontinuation in Some Patients With CML
June 12, 2020, Cancer Therapy Advisor
Updated Results Show Ongoing Treatment-Free Remission in CML Trial
June 6, 2019, Cancer Network
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
June 2, 2020, Frontiers in Oncology
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study
May 27, 2020, ACS Journals
Treatment-free Remission in Chronic Myeloid Leukemia: The Patient Perspective and Areas of Unmet Needs
May 26, 2020, PubMed
Possible Predictors of Treatment-Free Remission in Patients with CML
May 13, 2020, Cancer Network
Treatment-free remission in patients with chronic myeloid leukaemia
May 6, 2020, Nature
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
May 2020, Haematologica
Successful Treatment-Free Remission in Chronic Myeloid Leukaemia and Its Association With Reduced Immune Suppressors and Increased Natural Killer Cells
April 30, 2020, British Journal of Haematology
Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients
February 10, 2020, PubMed
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
January 1, 2020, PubMed
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
December 23, 2019, Blood Advances
CML Patient Views on Psychological Support During Treatment-Free Remission
December 13, 2019, Journal of Clinical Pathways
A new target for leukaemia patients seeking treatment free remission
December 6, 2019, SAHMRI
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
December 2019, ASH 2019
A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts
December 2019,ASH 2019
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
December 2019, ASH 2019
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update
December 2019, ASH 2019
Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
December 2019, ASH 2019
Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation – Results from Two Prospective Brazilian Trials
December 2019, ASH 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
November 25, 2019, Leukemia
Treatment-Free Remission at Heart of New CML Study
November 14, 2019, AJMC
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
November 13, 2019, ASH2019
Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)
November 13, 2019, Journal Blood
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
November 13, 2019, ASH Publications
Dr. Seet on Aspects of Treatment Discontinuation in CML
September 17, 2019, OncLive
Prolonged Treatment Free Remission In Chronic Myeloid Leukemia Patients With Previous BCR-ABL1 Kinase Domain Mutations
September 17, 2019, Haematologica
Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
September 3, 2019, Dovepress
Dr. Seet on the Need for Long-Term Outcome Data Regarding Treatment Discontinuation in CML
August 27, 2019, OncLive
Discontinuation Of Tyrosine Kinase Inhibitors In Patients With Chronic Myelogeneous Leukemia – You Can Do This At Home If You Read The Instructions
August 2019, Haematologica
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
August 13, 2019, Frontiers in Oncology
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
August 6, 2019, Frontiers in Oncology
TKI Dose Reduction Improves Treatment-Free Remission Protocols for Chronic Myeloid Leukemia
July 17, 2019, Oncology Nurse Advisor
Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
July 9, 2019, Cancer Medicine
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
July 4, 2019, PubMed
TKI Discontinuation Still an Unclear Picture in CML
June 6, 2019, OncLive
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May 14, 2019, PubMed
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation
May 13, 2019, PubMed
Reasons for TKI discontinuation ID'd in chronic myeloid leukemia
April 16, 2019, Medical Xpress
Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
April 3, 2019, The Oncologist
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
March 27, 2019, British Journal of Haematology
TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23, 2019, OncLive
ddPCR Brings Confidence to Leukemia Monitoring
January 3, 2019, Technology Networks
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
January 3, 2019, Journal of Hematology & Oncology
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
December 2, 2018, Nature
Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial
December 2018, ASH 2018
Association of Gene Expression Patterns in Bone Marrow Cells with Likelihood of Treatment Free Remission after TKI Discontinuation
December 2018, ASH 2018
Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study
December 2018, ASH 2018
Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study
December 2018, ASH 2018
Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)
December 2018, ASH 2018
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
October 2018, American Journal of Hematology
Recent Data Support TKI Discontinuation in Patients With CML
September 24, 2018, OncLive
Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML
July 14, 2018, OncLive
Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey (China)
June 15, 2018, PubMed
TREATMENT- FREE REMISSION UP TO 12 YEARS. INTERIM ANALYSIS OF A REGIONAL GERMAN CML - REGISTER. (A CONTRIBUTION OF GERMAN CML - ALLIANCE)
June 2018, EHA 2018
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
June 2018, EHA 2018
LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM
June 2018, EHA 2018
FINAL RESULTS OF THE DESTINY STUDY OF DE-ESCALATION AND STOPPING TREATMENT IN CHRONIC MYELOID LEUKAEMIA
June 2018, EHA 2018
PEG-INTERFERON ΑLPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP
June 2018, EHA 2018
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.
June 2018, ASCO 2018
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.
June 2018, ASCO 2018
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
June 2018, ASCO 2018
Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
June 2018, Clinical Lymphoma, Myeloma & Leukemia
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
May 3, 2018, PubMed
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
April 12, 2018, PubMed
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML
March 5, 2018, Oncology Nurse Advisor
Treatment-Free Remission Assessed After Nilotinib Discontinuation in CML
February 26, 2018, Monthly Prescribing Reference
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
February 26, 2018, Nature
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
February 22, 2018, PubMed
Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia
February 2018, Clinical Lymphoma, Myeloma & Leukemia
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
January 19, 2018, National Cancer Institute
Treatment-free remission in CML: who, how, and why? (Dr.François-Xavier Mahon)
December 8, 2017, PubMed
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors
December 2017, ASH 2017
Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) – Evaluation of Pioglitazone in Treatment-Free Remission
December 2017, ASH 2017
Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)
December 2017, ASH 2017
Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop
December 2017, ASH 2017
Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop
December 2017, ASH 2017
Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)
December 2017, ASH 2017
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
Treatment-free remission in patients with chronic myeloid leukemia
July 8, 2017, Pubmed
Patients Have Mixed Responses Regarding Discontinuing TKI Therapy for Chronic Myeloid Leukemia
April 26, 2019, Oncology Nurse Advisor
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
April 24, 2017, NCBI
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Risk & reward: Stopping a cancer drug to see if you're cured
March 2, 2017, Huffpost
CD86+ pDCs: A Marker for Treatment-free Remission in Chronic Myeloid Leukemia?
March 1, 2017, Cancer Therapy Advisor
CML: Less Frequent Monitoring of BCR-ABL1 May Not Affect Outcomes
February 28, 2017, Cancer Therapy Advisor
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
New CML Data Post Signs on Route to Treatment-Free Remission
February 10, 2017, Medscape
Immune reconstitution and remission in CML
2017, Blood
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop
December 5, 2016, ASH 2016
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 4, 2016, ASH 2016
Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan
December 3, 2016, ASH 2016
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 3, 2016, ASH 2016
Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML
December 3, 2016, ASH 2016
Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
December 3, 2016, ASH 2016
Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib – the Dasfree Study
December 3, 2016, ASH 2016
CML patient motivation for TFR remission attempts highlighted
October 28, 2016, medwireNews
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
September 2016, Cancer Medicine
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
July 29, 2016, Journal of Hematology & Oncology
The concept of treatment-free remission in chronic myeloid leukemia
June 3, 2016, Leukemia
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study (1)
June 2016, ASCO 2016
Moving treatment-free remission into mainstream clinical practice in CML
March 22, 2016, Journal Blood
Effect of Nilotinib Treatment Duration on Treatment-Free Remission in Patients with CP-CML
February 2016, The Oncology Pharamacist
How I Told My Kids I Quit the Medication That Saved My Life
January 4, 2016, Yahoo Parenting
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
December 7, 2015, ASH 2015
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
December 7, 2015, ASH 2015
When to Stop Beneficial Treatment in Chronic Myeloid Leukemia
November 25, 2015, Curetoday.com
Dasatinib Discontinuation After 1 Year Feasible in Certain Patients With CML
November 10, 2015, Cancer Therapy Advisor
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
October 19, 2015, PublMed
ASH-Report #1: Stopping CML treatment for therapy-free remission
January 25, 2015, CML Advocates Network
Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)
September 6, 2014, Journal Blood
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease
2014, ASCO
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
August 1, 2014, The ASCO Post
Musculoskeletal Pain on Stopping Imatinib: Should We Worry?
July 30, 2014, Medscape
Treatment-Free Remission by Tyrosine Kinase Inhibitor for Patients with Chronic Myeloid Leukemia
July 8, 2014, JSciMedCentral
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
June 2014, 2014 ASCO Annual Meeting
New Criterion for Restarting Therapy in CML
January 8, 2014, Medscape
Novartis provides update from treatment-free CML trial
September 23, 2013, Zenopa
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
December 21, 2023, Leukemia
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
November 10, 2023, Leukemia
Boosting immune system in chronic myeloid leukemia may lead to discontinuation of blood cancer drugs
November 6, 2023, Medical Xpress
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
November 2, 2023, Leukemia
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy
August 24, 2023, Blood
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
March 23, 2023, Frontiers
New therapy could help chronic myeloid leukemia patients live drug-free
March 2, 2023, The University of Adelaide
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
October 31, 2022, Dovepress
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
May 26, 2022, PubMed
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
April 7, 2022, PubMed
When is it safe to discontinue TKI therapy in people with chronic myeloid leukemia?
March 20, 2022, MedCity News
Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
November 20, 2021, PubMed
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML
November 2, 2021, PubMed
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
August 18, 2021, MDPI
Substudy to Assess CML Patients’ Perspectives on Treatment-Free Remission
June 25, 2021, Oncology Nurse Advisor
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Safe, Successful, Even Outside Clinical Trials
June 16, 2021, Oncology Nurse Advisor
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
May 26, 2021, Frontiers in Oncology
Updated Analysis of Data Demonstrates Efficacy of TFR in Chronic Myeloid Leukemia in Chronic Phase
April 9. 2021, Oncology Nurse Advisor
BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia
March 31, 2021, Oncology Nurse Advisor
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
February 15, 2021, Leukemia
Dr Atallah Assesses Outcomes Following the Discontinuation TKIs in CML
February 15,2021, Oncology Learning Network
TKI Discontinuation Found to Benefit PROs in CML, Study Says
February 6, 2021, AJMC
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML
December 15, 2020, National Cancer Institute
Clinical Challenges: Discontinuing TKIs in Chronic Myeloid Leukemia
December 11, 2020, Medpage Today
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study
December 5, 2020, ASH2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial
November 12, 2020, JamaOncology
TKI Discontinuation Safe in CML, Improved PROs
November 12, 2020, MedpageToday
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
November 10, 2020, Blood Advances
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
October 24, 2020, Taylor & Francis Online
New Path for Preventing Chronic Myelogenous Leukemia Relapse Discovered
September 21, 2020, GEN – Genetic Engineering & Biotechnology News
Evaluating treatment-free remission in patients with chronic myeloid leukemia (CML)
September 14, 2020, Medivizor
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
September 4, 2020, MDPI
Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
July 15, 2020, Clinical Lymphoma & Myeloma & Leukemia
CHARACTERIZATION OF PHENOTYPIC AND GENOTYPIC MARKERS AS PREDICTORS OF RELAPSE DURING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
SECOND GENERATION TYROSINE KINASE INHIBITORS IN THE FIRST-LINE CAN REDUCE TIME TO TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
EFFICACY AND SAFETY OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSED AFTER DISCONTINUATION OF IMATINIB FOR TREATMENT-FREE REMISSION: RESULTS OF THE FRENCH NILO POST-STIM STUDY
June 2020, EHA 2020
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY.
June 2020, EHA 2020
LATE MOLECULAR RECURRENCES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA EXPERIENCING TREATMENT FREE REMISSION.
June 2020, EHA 2020
HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY
June 2020, EHA 2020
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY
June 2020, EHA 2020
HLA POLYMORPHISMS PREDICT TREATMENT-FREE REMISSION FOLLOWING TKI DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020
DOSE REDUCTION OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH MAJOR AND DEEP MOLECULAR RESPONSE
June 2020, EHA 2020
Study Provides Support for TKI Discontinuation in Some Patients With CML
June 12, 2020, Cancer Therapy Advisor
Updated Results Show Ongoing Treatment-Free Remission in CML Trial
June 6, 2019, Cancer Network
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
June 2, 2020, Frontiers in Oncology
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study
May 27, 2020, ACS Journals
Treatment-free Remission in Chronic Myeloid Leukemia: The Patient Perspective and Areas of Unmet Needs
May 26, 2020, PubMed
Possible Predictors of Treatment-Free Remission in Patients with CML
May 13, 2020, Cancer Network
Treatment-free remission in patients with chronic myeloid leukaemia
May 6, 2020, Nature
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
May 2020, Haematologica
Successful Treatment-Free Remission in Chronic Myeloid Leukaemia and Its Association With Reduced Immune Suppressors and Increased Natural Killer Cells
April 30, 2020, British Journal of Haematology
Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients
February 10, 2020, PubMed
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
January 1, 2020, PubMed
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
December 23, 2019, Blood Advances
CML Patient Views on Psychological Support During Treatment-Free Remission
December 13, 2019, Journal of Clinical Pathways
A new target for leukaemia patients seeking treatment free remission
December 6, 2019, SAHMRI
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
December 2019, ASH 2019
A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts
December 2019,ASH 2019
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
December 2019, ASH 2019
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update
December 2019, ASH 2019
Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
December 2019, ASH 2019
Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation – Results from Two Prospective Brazilian Trials
December 2019, ASH 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
November 25, 2019, Leukemia
Treatment-Free Remission at Heart of New CML Study
November 14, 2019, AJMC
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
November 13, 2019, ASH2019
Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)
November 13, 2019, Journal Blood
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
November 13, 2019, ASH Publications
Dr. Seet on Aspects of Treatment Discontinuation in CML
September 17, 2019, OncLive
Prolonged Treatment Free Remission In Chronic Myeloid Leukemia Patients With Previous BCR-ABL1 Kinase Domain Mutations
September 17, 2019, Haematologica
Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
September 3, 2019, Dovepress
Dr. Seet on the Need for Long-Term Outcome Data Regarding Treatment Discontinuation in CML
August 27, 2019, OncLive
Discontinuation Of Tyrosine Kinase Inhibitors In Patients With Chronic Myelogeneous Leukemia – You Can Do This At Home If You Read The Instructions
August 2019, Haematologica
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
August 13, 2019, Frontiers in Oncology
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
August 6, 2019, Frontiers in Oncology
TKI Dose Reduction Improves Treatment-Free Remission Protocols for Chronic Myeloid Leukemia
July 17, 2019, Oncology Nurse Advisor
Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
July 9, 2019, Cancer Medicine
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
July 4, 2019, PubMed
TKI Discontinuation Still an Unclear Picture in CML
June 6, 2019, OncLive
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May 14, 2019, PubMed
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation
May 13, 2019, PubMed
Reasons for TKI discontinuation ID'd in chronic myeloid leukemia
April 16, 2019, Medical Xpress
Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
April 3, 2019, The Oncologist
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
March 27, 2019, British Journal of Haematology
TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23, 2019, OncLive
ddPCR Brings Confidence to Leukemia Monitoring
January 3, 2019, Technology Networks
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
January 3, 2019, Journal of Hematology & Oncology
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
December 2, 2018, Nature
Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial
December 2018, ASH 2018
Association of Gene Expression Patterns in Bone Marrow Cells with Likelihood of Treatment Free Remission after TKI Discontinuation
December 2018, ASH 2018
Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study
December 2018, ASH 2018
Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study
December 2018, ASH 2018
Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)
December 2018, ASH 2018
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
October 2018, American Journal of Hematology
Recent Data Support TKI Discontinuation in Patients With CML
September 24, 2018, OncLive
Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML
July 14, 2018, OncLive
Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey (China)
June 15, 2018, PubMed
TREATMENT- FREE REMISSION UP TO 12 YEARS. INTERIM ANALYSIS OF A REGIONAL GERMAN CML - REGISTER. (A CONTRIBUTION OF GERMAN CML - ALLIANCE)
June 2018, EHA 2018
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
June 2018, EHA 2018
LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM
June 2018, EHA 2018
FINAL RESULTS OF THE DESTINY STUDY OF DE-ESCALATION AND STOPPING TREATMENT IN CHRONIC MYELOID LEUKAEMIA
June 2018, EHA 2018
PEG-INTERFERON ΑLPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP
June 2018, EHA 2018
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.
June 2018, ASCO 2018
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.
June 2018, ASCO 2018
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
June 2018, ASCO 2018
Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
June 2018, Clinical Lymphoma, Myeloma & Leukemia
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
May 3, 2018, PubMed
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
April 12, 2018, PubMed
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML
March 5, 2018, Oncology Nurse Advisor
Treatment-Free Remission Assessed After Nilotinib Discontinuation in CML
February 26, 2018, Monthly Prescribing Reference
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
February 26, 2018, Nature
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
February 22, 2018, PubMed
Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia
February 2018, Clinical Lymphoma, Myeloma & Leukemia
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
January 19, 2018, National Cancer Institute
Treatment-free remission in CML: who, how, and why? (Dr.François-Xavier Mahon)
December 8, 2017, PubMed
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors
December 2017, ASH 2017
Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) – Evaluation of Pioglitazone in Treatment-Free Remission
December 2017, ASH 2017
Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)
December 2017, ASH 2017
Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop
December 2017, ASH 2017
Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop
December 2017, ASH 2017
Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)
December 2017, ASH 2017
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
Treatment-free remission in patients with chronic myeloid leukemia
July 8, 2017, Pubmed
Patients Have Mixed Responses Regarding Discontinuing TKI Therapy for Chronic Myeloid Leukemia
April 26, 2019, Oncology Nurse Advisor
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
April 24, 2017, NCBI
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Risk & reward: Stopping a cancer drug to see if you're cured
March 2, 2017, Huffpost
CD86+ pDCs: A Marker for Treatment-free Remission in Chronic Myeloid Leukemia?
March 1, 2017, Cancer Therapy Advisor
CML: Less Frequent Monitoring of BCR-ABL1 May Not Affect Outcomes
February 28, 2017, Cancer Therapy Advisor
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
New CML Data Post Signs on Route to Treatment-Free Remission
February 10, 2017, Medscape
Immune reconstitution and remission in CML
2017, Blood
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop
December 5, 2016, ASH 2016
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 4, 2016, ASH 2016
Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan
December 3, 2016, ASH 2016
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
December 3, 2016, ASH 2016
Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML
December 3, 2016, ASH 2016
Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
December 3, 2016, ASH 2016
Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib – the Dasfree Study
December 3, 2016, ASH 2016
CML patient motivation for TFR remission attempts highlighted
October 28, 2016, medwireNews
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
September 2016, Cancer Medicine
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
July 29, 2016, Journal of Hematology & Oncology
The concept of treatment-free remission in chronic myeloid leukemia
June 3, 2016, Leukemia
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study (1)
June 2016, ASCO 2016
Moving treatment-free remission into mainstream clinical practice in CML
March 22, 2016, Journal Blood
Effect of Nilotinib Treatment Duration on Treatment-Free Remission in Patients with CP-CML
February 2016, The Oncology Pharamacist
How I Told My Kids I Quit the Medication That Saved My Life
January 4, 2016, Yahoo Parenting
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
December 7, 2015, ASH 2015
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
December 7, 2015, ASH 2015
When to Stop Beneficial Treatment in Chronic Myeloid Leukemia
November 25, 2015, Curetoday.com
Dasatinib Discontinuation After 1 Year Feasible in Certain Patients With CML
November 10, 2015, Cancer Therapy Advisor
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
October 19, 2015, PublMed
ASH-Report #1: Stopping CML treatment for therapy-free remission
January 25, 2015, CML Advocates Network
Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)
September 6, 2014, Journal Blood
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease
2014, ASCO
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
August 1, 2014, The ASCO Post
Musculoskeletal Pain on Stopping Imatinib: Should We Worry?
July 30, 2014, Medscape
Treatment-Free Remission by Tyrosine Kinase Inhibitor for Patients with Chronic Myeloid Leukemia
July 8, 2014, JSciMedCentral
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
June 2014, 2014 ASCO Annual Meeting
New Criterion for Restarting Therapy in CML
January 8, 2014, Medscape
Novartis provides update from treatment-free CML trial
September 23, 2013, Zenopa
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice